Le Lézard
Classified in: Health, Business
Subjects: TNM, AVO

APCI to Feds: Stop Merger of Drug Middlemen

BESSEMER, Ala., June 30, 2022 /PRNewswire/ -- Pharmacy benefit manager (PBM) Prime Therapeutics' proposed acquisition of rival PBM Magellan Rx Management "raises serious anti-competitive concerns" and should be blocked, according to a letter sent today from American Pharmacy Cooperative, Inc. (APCI) to the U.S. Department of Justice and the Federal Trade Commission.

Integration in the PBM market has increased prices and had anti-competitive effects.

In its letter to the agencies, APCI not only opposed the proposed acquisition but also called for a review of Magellan's acquisition by Medicaid Managed Care organization Centene in 2021 and its decision to unload the PBM in such a short time frame.

In the 13-page letter, APCI Director of Healthcare Policy and General Counsel Greg Reybold wrote:

Simply put, Prime's acquisition is likely to create more conflicts of interest, reduce competition, and lead to greater inefficiencies in an already inefficient and flawed system. Rather than allowing this merger to proceed, the Agencies would do well to utilize their authority to not only stop this proposed acquisition but also investigate the premise for Centene's acquisition of Magellan Health and determine whether it is appropriate to unwind that merger in light of Centene's past behavior on the PBM space combined with the proposed divestiture seemingly standing in contrast to the claimed reasons for its acquisition in the first place.

"We have seen time and time again how these PBM acquisitions and mergers have turned out to be detrimental for patients, taxpayers, and small businesses," said Tim Hamrick, APCI Chief Executive Officer. "We urge the FTC and the Department of Justice to take a long, hard look at this proposed merger and do what is right not only for patients and our member pharmacies but for all Americans."

"The largest PBMs in the U.S. have created a prescription drug pricing and access problem," Reybold said. "Six PBMs handle more than 95 percent of the market for prescription claims, and we continue to see increasing prescription prices and reduced access to lifesaving medications for patients. While these middlemen claim to bring market efficiencies to the prescription drug chain, the reality is integration in the PBM market has increased prices and had anti-competitive effects."

About APCI

APCI is a member-owned cooperative of more than 1,600 member pharmacies in 30 states. Established in 1984 and headquartered in Bessemer, Ala., APCI is proud to lead the fight for prescription drug pricing transparency and reform.

SOURCE American Pharmacy Cooperative, Inc.

These press releases may also interest you

at 11:37
The Minister of Families, Children and Social Development, Karina Gould will be in Trois-Rivières to announce additional passport pick-up locations across the country. The Minister will be accompanied by Stéphane Lauzon, Parliamentary Secretary to...

at 11:31
Emergency Safety Solutions, Inc. (ESS), creator of the Hazard Enhanced Location Protocol (H.E.L.P.tm?) which revolutionizes vehicle hazard warning systems to prevent crashes into disabled and vulnerable vehicles and their occupants, announced today...

at 11:30
FSRA has released its annual report on the funding of defined benefit pension plans in Ontario. FSRA estimated the projected funded ratio of the plans has improved slightly. In general, this means during the report period, plans remained well...

at 11:30
The Bank of America appears to be bullish on the future of uranium spot prices The rising support for nuclear energy and tight supply could see uranium spot prices return to US$70/lb by 2023, according to Bank of America (BoA). In a recent article in...

at 11:30
S&P Dow Jones Indices and Experian released today data through July 2022 for the S&P/Experian Consumer Credit Default Indices. The indices represent a comprehensive measure of changes in consumer credit defaults and show that the composite rate rose...

at 11:30
RCN Capital, the leading nationwide private lender for real estate investors, has been named on the 2022 Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America, ranking No. 2083. RCN Capital also ranked No....

News published on 30 june 2022 at 19:23 and distributed by: